It's mostly provincial where that needs to come from, because that's where the delivery of the health care system happens.
What you have to do is develop a process, like MaRS EXCITE, that identifies devices that are disruptive, that are really adding value. When you go though the process of doing that, to pick those particular products.... There are over a thousand class III and class IV agents approved by Health Canada every year, so you're going to have to choose the products. As well, you're going to have to be realistic about it in terms of where it is.
It's to have money for those innovative therapies that are really going to add to patient health outcomes and reduce cost to the system or make things more effective. I think that is a provincial mandate.